aTyr Pharma Derivative Claims Investigation: Johnson Fistel Examines Fiduciary Breaches

Johnson Fistel is investigating potential derivative claims on behalf of aTyr Pharma, Inc. shareholders regarding alleged fiduciary breaches tied to disclosures around the Phase 3 EFZO-FIT clinical trial. The investigation covers November 7, 2024 through September 12, 2025. Shareholders who continuously held their shares before November 7, 2024 and continue to hold them may have standing to pursue derivative claims. Johnson Fistel is examining whether aTyr's board failed to properly oversee clinical disclosure controls and permitted overly optimistic representations.